EntreMed (ENMD) Presented Kinase Inhibitor, ENMD-2076, During AACR Special Session
More News related to ENMD
- EntreMed's ENMD-2076 Active in Solid and Hematological Cancers
- EntreMed Inc. (ENMD) Posts Break-Even Q3 EPS, 4c Better Y/Y
- EntreMed Reports Third Quarter 2009 Financial Results
- Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
- EntreMed (ENMD) Presents ENMD-2076 Data at ASCO
More News related to Corporate News
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
EntreMed, Inc. (Nasdaq: ENMD) announced the presentation of preclinical and mechanism of action data for its selective kinase inhibitor, ENMD-2076. On Sunday, April 13, 2008, Mark R. Bray, Ph.D., Vice President, Research, gave an oral presentation during the "New Drugs on the Horizon 2" symposium at the American Association for Cancer Research (AACR) Annual Meeting being held this week in San Diego, California.
In preclinical studies, ENMD-2076 demonstrated potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. ENMD-2076 is an orally active, multi-kinase inhibitor that has shown an acceptable toxicity profile in multiple preclinical studies without cardiovascular effects.
EntreMed, Inc. (EntreMed) is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells and the blood vessels that nourish them. [SM]
Related Categories
Corporate NewsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
